KaNDy Therapeutics is a clinical-stage company focused on optimising the potential of NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions, with an initial focus on symptoms of the menopause.
1
Funding Rounds
$32.5m
Money raised
Access comprehensive data and insights available only to Seedtable members
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide